Session 2

Traversing the BBB—Pre-Clinical to Clinical Translation

Co-Moderators:

E. Antonio Chiocca, Harvard Medical School
Danica Stanimirovic, National Research Council of Canada
Session I: Traversing the BBB - Pre-clinical to Clinical Translation

Session Overview
DANICA STANIMIROVIC, National Research Council of Canada (CO-MODERATOR)
E. ANTONIO CHIOCCA, Harvard Medical School (CO-MODERATOR)

Presentations
BALU CHAKRAVARTHY, National Research Council of Canada
ALEXANDRA GOLBY, Brigham and Women's Hospital
RUBEN BOADO, Armagen
DAHAVALKUMAR SHAH, State University of New York at Buffalo

Discussion
Session I: Traversing the BBB - Pre-clinical to Clinical Translation

Session Objectives:

- Discuss the translation – from late preclinical work to clinical trials – of delivery strategies for traversing the BBB, including delivery of synthetic molecules, biologics, and gene therapy.
- Describe the limitations of current methods for traversing the BBB and identify research and other potential next steps that would move the field forward.
Challenges of translation in CNS/BBB

• Relevance of animal models

• Small brain vs. big brain

• Species differences

• Planning pre-clinical studies to ‘mimic’ clinical studies (outcome measures)

• Biomarkers of target engagement (and surrogates)

• Toxicity, immunogenicity

• PKPD – Scale up across species, physiological modeling